Aurobindo Pharma Limited Share Price & Analysis

Aurobindo Pharma acquires European pharma firm

*Aurobindo Pharma acquires European pharma firm.* The acquisition is valued at **₹6,200 crore**, boosting its European footprint. This strategic move enhances Aurobindo’s generics portfolio and manufacturing capabilities. The deal is expected to close by Q4FY25. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Aurobindo completes $210M Lannett acquisition in US

*Aurobindo completes $210M Lannett acquisition in US* — Aurobindo Pharma USA Inc., a wholly owned subsidiary, has completed the acquisition of Lannett Company Inc. for **$210 million**. This strategic move strengthens Aurobindo’s presence in the US generics market. The integration is expected to enhance product portfolio and revenue streams. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Aurobindo Pharma USA gets FTC nod to buy Lannett

*Aurobindo Pharma USA gets FTC nod to buy Lannett*. The acquisition of Lannett Company has received approval from the U.S. Federal Trade Commission, clearing a key regulatory hurdle. This deal significantly expands Aurobindo’s presence in the U.S. generics market. The transaction is expected to close soon, pending final conditions. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Mergers

Aurobindo Pharma secures FTC nod for Lannett acquisition

*Aurobindo Pharma secures FTC nod for Lannett acquisition.* The approval clears a key regulatory hurdle for the acquisition of Lannett’s business in the US. This paves the way for Aurobindo to expand its presence in the competitive US generics market. The deal strengthens its product portfolio and manufacturing footprint. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Aurobindo Pharma unit flagged OAI by USFDA

*Aurobindo Pharma slips on USFDA's OAI classification of Eugia Unit-III.* The USFDA has issued an Official Action Initiated (OAI) status for the facility following an inspection, triggering concerns over potential supply disruptions. This could delay product approvals and impact export revenues. **No major financial penalties yet**, but compliance resolution is critical. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Regulatory

Aurobindo Pharma transfers products business to subsidiary

*Aurobindo Pharma transfers products business to subsidiary* Aurobindo Pharma Limited has transferred its products business to Auropharm Limited, a wholly-owned subsidiary. This move is part of internal restructuring and consolidation within the group. No financial impact is expected as it’s a demerger among group entities. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Restructuring

Aurobindo Pharma shares unchanged after newspaper publication notice

*Aurobindo Pharma shares unchanged after newspaper publication notice.* The filing is a routine disclosure and contains no new financial or operational update. It reflects compliance with regulatory requirements under the Companies Act. No material business development was disclosed. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Aurobindo Pharma hosts analyst and investor meet

*Aurobindo Pharma hosts analyst and investor meet.* The company provided updates during its scheduled investor interaction. No major financial announcements or strategic shifts were disclosed. The session focused on ongoing business performance and market outlook. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Aurobindo Pharma gets USFDA nod for Tofacitinib tablets

*Aurobindo Pharma gets USFDA nod for Tofacitinib tablets* – a generic version of Xeljanz used to treat rheumatoid arthritis. The approval allows the company to launch the **5 mg** tablet in the US market, expanding its portfolio. This adds to Aurobindo’s growing list of **~400** ANDA approvals. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Aurobindo gets USFDA nod for Tofacitinib tablets

*Aurobindo gets USFDA nod for Tofacitinib tablets* — Aurobindo Pharma has received final approval from the USFDA for its generic Tofacitinib tablets, used to treat rheumatoid arthritis. The approval allows the company to launch the product immediately, expanding its footprint in the US market. This positions Aurobindo to capture a share of the **$1.2 billion** annual market. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA